Charles River Laboratories International, Inc. has entered into a definitive agreement to acquire the CRO services division of Galapagos NV, which includes both Argenta and BioFocus, for $179 million and future performance payments of as much as $7 million. These businesses provide integrated drug discovery services, with a predominant focus on in vitro capabilities. The acquisition positions Charles River as a full service, early-stage CRO, with in vitro and in vivo capabilities from target dis...